Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
1. To evaluate efficacy, safety, and feasibility of maintenance therapy with Cetuximab
combined with irinotecan or fluorouracil after Cetuximab plus irinotecan and
fluorouracil(FOLFIRI) in patients with incurable colorectal cancer.
2. The relevant phase III studies reported that the progression free-survival of cetuximab
combined with FOLFIRI in advanced colorectal cancer was 4.3 months up to 6.8 months.
This study assumed that the progression free-survival was 5.1 months which was not inferior
to the continuous chemotherapy